close

Mergers and Acquisitions

1 2 3 4 33
Number of results: 642
Date Acquired company Acquiring company Amount Related
2018-01-22 Bioverativ (USA - CA) Sanofi (France) $11.6 billion (€ 9.47 billion) Rare diseases - Genetic diseases - Hematological diseases
2018-01-22 Juno Therapeutics (USA - WA) Celgene (USA _ NJ) $9 billion (€ 7.34 billion) Cancer - Oncology - Hematological diseases
2018-01-08 Ablynx (Belgium) Novo Nordisk (Denmark) € 2.6 billion Hematological diseases - Inflammatory diseases
2018-01-08 The Medicines Company's infectious diseases business unit (USA - NJ) Melinta Therapeutics (USA) $270 million infectious diseases
2018-01-05 Tigenix (Belgium) Takeda Pharmaceutical (Japan) € 520 million
2017-12-29 Sellas Life Sciences (Bermuda) Galena BioPharma (USA - OR) Cancer - Oncology
2017-12-26 Sucampo Pharmaceuticals (USA - MA) Mallinckrodt (UK) $1.2 Billion Rare diseases
2017-12-23 Discuva (UK) Summit (UK) £10 million Infectious diseases
2017-12-21 Ignyta (USA - CA) Roche (Switzerland) $ 1.7 billion Cancer - Oncology
2017-12-21 Pasteur Group (Brazil) Eurofins Scientific (Luxembourg) undisclosed Diagnostic
2017-12-20 Alizé Pharma (France) Millendo Therapeutics (USA - Mich) undisclosed Endocrine diseases - Hormonal diseases
2017-12-07 Cell Design Labs (USA - CA) Gilead Sciences (USA - CA) $567 million Technology - Services - Cancer - Oncology
2017-12-07 Eurotrials (Portugal) CTI Clinical Trial and Consulting Services (CTI) (USA - KY) undisclosed
  • clinical research - CRO
2017-11-07 Dimension Therapeutics (USA - MA) Ultragenyx Pharmaceuticals (USA - CA) $ 151 million Rare diseases - Genetic diseases
2017-10-03 Kite Pharma (US - CA) Gilead Sciences (USA - CA) $11.9 billion Cancer - Oncology - Cell therapy
2017-10-02 RegenxBio (USA - MD) Dimension Therapeutics (USA - MA) Rare diseases - Genetic diseases
2017-09-18 EAG Laboratories (USA - CA) Eurofins Scientific (Luxembourg) $ 780m Technology - Services
2017-09-06 Rigontec (Germany) Merck&Co (USA - NJ) up to $ 464 million Cancer - Oncology
2017-09-01 Merck KGaA's biosimilar business (Germany) Fresenius Kabi (Germany) €656 million plus royalties on future product sales Biosimilar
2017-08-31 Bertin Pharma (France) Oncodesign (France) undisclosed Technology - Services - Immunological diseases